公开(公告)号：US11674155B2

公开(公告)日：2023-06-13

申请号：US17817877

申请日：2022-08-05

Applicant: CELLECTIS

Inventor： Jean-Pierre Cabaniols ,  Jean-Charles Epinat ,  Philippe Duchateau

IPC: C12N15/86 ,  C12N5/0783 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/90

CPC classification number: C12N15/86 ,  C12N5/0636 ,  C12N9/22 ,  C12N13/00 ,  C12N15/113 ,  C12N15/902 ,  C12N2310/20 ,  C12N2510/00 ,  C12N2800/80

Abstract: The invention pertains to the field of adaptive cell immunotherapy. It aims at reducing the occurrence of translocations and cell deaths when several specific endonuclease reagents are used altogether to genetically modify primary immune cells at different genetic loci. The method of the invention allows to yield safer immune primary cells harboring several genetic modifications, such as triple or quadruple gene inactivated cells, from populations or sub-populations of cells originating from a single donor or patient, for their subsequent use in therapeutic treatments.

公开(公告)号：US20220010292A1

公开(公告)日：2022-01-13

申请号：US17489454

申请日：2021-09-29

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva ,  Alexandre Juillerat ,  Marine Beurdeley

IPC: C12N9/16 ,  C12N15/63 ,  C07K14/195 ,  C12N5/071 ,  C12N5/10 ,  C12N9/22

Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENs) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.

公开(公告)号：US11220683B2

公开(公告)日：2022-01-11

申请号：US16379073

申请日：2019-04-09

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Julien Valton

IPC: C12N15/10 ,  C12N15/85 ,  C07K14/47 ,  C12N9/22 ,  G01N33/53

Abstract: The present invention relates to polypeptides and more particularly to Transcription Activator-Like Effector derived proteins that allow to efficiently target and/or process nucleic acids. Particularly, the present invention reports the characterization of TALE derived proteins that can efficiently target methylated DNA. The present invention more specifically relates to TALE derived proteins that allow activation of methylated promoters responsible for gene silencing.

公开(公告)号：US11186824B2

公开(公告)日：2021-11-30

申请号：US15556558

申请日：2016-03-11

Applicant: Cellectis

Inventor： Philippe Duchateau ,  Jean-Pierre Cabaniols ,  Julien Valton ,  Laurent Poirot

IPC: A61K35/17 ,  A61K48/00 ,  C12N5/0783 ,  C12N5/00 ,  C07K14/005 ,  C07K14/705 ,  C07K14/74 ,  C07K16/28 ,  C12N9/22 ,  C12N15/11 ,  A61K39/00

Abstract: The present invention relates to methods for developing engineered immune cells such as T-cells for immunotherapy that have a higher potential of persistence and/or engraftment in host organism. IN particular, this method involves an inactivation of at least one gene involved in self/non self recognition, combined with a step of contact with at least one non-endogenous immunosuppressive polypeptide. The invention allows the possibility for a standard and affordable adoptive immunotherapy, whereby the risk of GvH is reduced.

公开(公告)号：US10988542B2

公开(公告)日：2021-04-27

申请号：US15752195

申请日：2016-08-24

Applicant: CELLECTIS

Inventor： Alexandre Juillerat ,  Philippe Duchateau ,  Laurent Poirot

IPC: C07K14/725 ,  C07K14/72 ,  C07K16/28 ,  A61K35/17 ,  A61P35/00 ,  A61K31/436 ,  A61K38/00

Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.

公开(公告)号：US20210100839A1

公开(公告)日：2021-04-08

申请号：US16498276

申请日：2018-03-30

Applicant: CELLECTIS SA

Inventor： Cecile Schiffer-Mannioui ,  Philippe Duchateau ,  Anne-Sophie Gautron

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K14/705

Abstract: The present invention relates to new CD22 Chimeric Antigen Receptors (CD22 CAR), an engineered immune cell endowed with said new CD22 CAR and comprising at least inactivated TRAC gene for use in therapy. The engineered immune cells endowed with such CARs are particularly suited for treating relapsed refractory CD22 expressing cancers.

公开(公告)号：US10894093B2

公开(公告)日：2021-01-19

申请号：US16092417

申请日：2017-04-13

Applicant: CELLECTIS

Inventor： Julien Valton ,  Veronique Zennou ,  Philippe Duchateau ,  Laurent Poirot

IPC: C12N5/0783 ,  C12N15/113 ,  A61P31/00 ,  A61K48/00 ,  A61K35/17 ,  C07K14/725 ,  A61P35/00

Abstract: The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering drug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific drug in case of occurrence of a serious adverse even. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer.

公开(公告)号：US10526406B2

公开(公告)日：2020-01-07

申请号：US15111441

申请日：2015-01-14

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Julien Valton

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C12N5/0783 ,  C07K14/705 ,  A61K38/00

Abstract: The present invention relates to a new generation of chimeric antigen receptors (CAR), under single-chain or multi-chain forms, the specificity of which, to a desired antigen, is conferred by a VNAR polypeptide derived from monomeric antibodies from cartilaginous fish. Such CARs, which aim to redirect immune cell specificity toward selected undesired malignant cells, are compact and thus particularly adapted to target hollow antigens such as ions channels of efflux pumps present at the surface of drug-resistant cells. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy.

公开(公告)号：US10472396B2

公开(公告)日：2019-11-12

申请号：US14696920

申请日：2015-04-27

Applicant: CELLECTIS

Inventor： Claudia Bertonati ,  Philippe Duchateau ,  Alexandre Juillerat ,  George Silva ,  Julien Valton

IPC: C12N9/22 ,  C12N15/62 ,  C07K14/195 ,  A01K67/027 ,  C12N15/87 ,  C12N15/90

Abstract: The present invention concerns new modular base-per-base specific nucleic acid binding domains (MBBBD) derived from newly identified proteins from the bacterial endosymbiont Burkholderia Rhizoxinica and their use for engineering nucleic acid processing enzymes, such as specific endonucleases or transcription activators.

公开(公告)号：US10239948B2

公开(公告)日：2019-03-26

申请号：US15106783

申请日：2014-12-19

Applicant: CELLECTIS

Inventor： Alexandre Juillerat ,  Claudia Bertonati ,  Julien Valton ,  Philippe Duchateau ,  Laurent Poirot

IPC: C07K14/47 ,  C07K16/30 ,  C07K16/46 ,  C07K16/28

Abstract: The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments.